Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
about
Discovery of 4-Aryl-2-benzoyl-imidazoles as tubulin polymerization inhibitor with potent antiproliferative properties.Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
P2860
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
@en
type
label
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
@en
prefLabel
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
@en
P2093
P2860
P1476
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
@en
P2093
Chien-Ming Li
Duane D Miller
James T Dalton
Jianjun Chen
Linda M Snyder
Mara N Dalton
Ramesh Narayanan
Sunjoo Ahn
Terrence A Costello
P2860
P304
P356
10.1007/S11095-012-0814-5
P577
2012-07-04T00:00:00Z